期刊文献+

RP-HPLC法测定人血浆中磷酸西他列汀药物含量 被引量:2

Determination of Sitagliptin Phosphate in Human Plasma by RP-HPLC
下载PDF
导出
摘要 目的建立测定人血浆中磷酸西他列汀含量的高效液相色谱法。方法采用Symmetrix ODS-H为分析柱,甲醇-0.1%高氯酸水溶液(40:60)为流动相;流速为1.0mL·min^-1,检测波长为268nm,采用外标法定量测定。结果进样浓度在5~500μg·mL^-1范围内与峰面积呈良好线性关系,r=0.9993,方法回收率为96.1%-100.9%。最低检测限为2μg·mL^-1。日间、日内精密度均小于4%。结论此方法操作简便、灵敏,重复性好,适用于人血浆中磷酸西他列汀含量的测定。 Objective To establish RP-HPLC method for determination of sitagliptin phosphate in human plasma. Methods A Symmetrix ODS-H column was used with methanol-0.1% perchloric acid solution (40 : 60) as mobile phase. The flow rate was 1.0mL·min^-1 and UV detection wavelength was 268nm. Results The linear range. 5-500μg ·mL^-1 , r=0. 9993. Limit of detection (LOD) 2μg·mL^-1. The relative standard deviations of inter day and intra-day were less than 4% (n= 5). Conclusions This method is simple, sensitive and reproducible. It is suitable for determination of sitagliptin phosphate in human plasma.
出处 《中国药事》 CAS 2009年第8期758-760,共3页 Chinese Pharmaceutical Affairs
关键词 RP—HPLC 人血浆 磷酸西他列汀 RP-HPLC sitagliptin phosphate human plasma
  • 相关文献

参考文献12

  • 1许菁,王玉丽,徐为人,张士俊.治疗2型糖尿病的新型药物——西他列汀[J].中国药物与临床,2007,7(11):861-863. 被引量:8
  • 2Mu J, Woods J, Zhou Y P, et al. Chronic. lnhibiton of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic { beta} -cell mass and function in a rodent model of type2 diabetes[J].Diabetes, 2006, 55 (6):1695-1704.
  • 3Rosenstock J, Brazg R, Andryuk P J. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added lo ongoing pioglitazone therapy in patients with type 2 diabetes: a 24 week, multicenter, randomized, double-blind, placebocontrolled, parallel-group study [J]. Clin Ther, 2006, 28 (10):1556-1568.
  • 4Gallwitz B. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes [J].Drugs Today (Barc), 2007, 43 (10): 681-689.
  • 5Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes[J]. Journal of clinical Pratice, 2006, 60 (11): 1454-1454.
  • 6Herman G, Hanefeld M, Wu M, et al. effect of MK-0431, a dipeptidyl peptidase Ⅳ (DPP Ⅳ) inhibitor on glycaemic control after 12 weeks in patients with type 2 diabetes [J]. Diabetes, 2005, 54 (suppl 1): A134, A541-541.
  • 7Charbonnel B, karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone[J]. Diabetes Care, 2006, 29 (12): 2638 2638.
  • 8Mistry G C, Bergman A J, Luo W L, et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects [J].Clin Pharmacol, 2007, 47 (2):159-164.
  • 9Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycemic control and beta-cell function in patients with type 2 diabetes [J]. Diabetes Obes Metab, 2007, 9 (2) : 186-193.
  • 10Wei Zeng, Donald G Musson, Alison L Fisher, et al. Determination of MK 0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry[J].Rapid Commun Mass Spectrom, 2006, 20 (8):1169-1175.

二级参考文献15

  • 1Gallwitz B.Therapies for the treatment of type 2 diabetes mellitus based on incretinaction.Minerva Endocrinol,2006,31(2):133-147.
  • 2Ahren B,Landin-olsson M,Jansson PA,et al.Inhibition of dipeptidyl peptidase-4 reduces glycemia,sustains insulin levels,and reduces glucagon levels in type 2 diabetes.J Clin Endocrinol Metab,2004,89(5):2078-2084.
  • 3Mu J,Woods J,Zhou YP,et al.Chronic Inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic {beta}-cell mass and function in a rodent model of type 2 diabetes.Diabetes,2006,55(6):1695-1704.
  • 4Drucker DJ,Nauck MA.The incretin system:glucagons-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.Lancet,2006,368(9548):1696-1705.
  • 5Aschner P,Kipnes MS,Lunceford JK,et al.Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.Diabetes care,2006,29(12):2632-2637.
  • 6Kim D,Wang L,Beconi M,et al.(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:a potent,orally active dipeptidyl peptidase-Ⅳ inhibitor for the treatment of type 2 diabetes.J Med Chem,2005,48(1):141-151.
  • 7Herman GA,Berqman A,Stevens C,et al.Effect of single oral doses of sitagliptin,a dipeptidyl peptidase-4 inhibitor,on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.Clin Endocrinol Metab,2006,91(11):4612-4619.
  • 8Miller S,Stonge EL.Sitagliptin:a dipeptidyl peptidase Ⅳ Inhibitor for the treatment of type 2 diabetes.Ann Pharm,2006,40(7-8):1336-1343.
  • 9Scott R,Wu M,Sanchez M,et al.Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.Int J Clin Pract,2007,61(1):171-180.
  • 10Charbonnel B,Karasik A,Liu J,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.Diabetes Care,2006,29 (12):2638-2643.

共引文献7

同被引文献10

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部